In this study, we present efavirenz physiologically based pharmacokinetic (PBPK) model development as an example of our best practice approach that uses a stepwise approach to verify the different components of the model. First, a PBPK model for efavirenz incorporating in vitro and clinical pharmacokinetic (PK) data was developed to predict exposure following multiple dosing (600 mg q.d.). Alfentanil i.v. and p.o. drug-drug interaction (DDI) studies were utilized to evaluate and refine the CYP3A4 induction component in the liver and gut. Next, independent DDI studies with substrates of CYP3A4 (maraviroc, atazanavir, and clarithromycin) and CYP2B6 (bupropion) verified the induction components of the model (area under the curve [AUC] ratios within 1.0-1.7-fold of observed). Finally, the model was refined to incorporate the fractional contribution of enzymes, including CYP2B6, propagating autoinduction into the model (Racc 1.7 vs. 1.7 observed). This validated mechanistic model can now be applied in clinical pharmacology studies to prospectively assess both the victim and perpetrator DDI potential of efavirenz. CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 367-376; doi:10.1002/psp4.12088; published online 20 July 2016.
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
þ Several efavirenz PBPK models have been used to support the clinical pharmacology reviews of new drug applications. There are literature reports that show the application of PBPK models to predict the interindividual variability in efavirenz PK and to support dose adjustment.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ We sought to develop a unified mechanistic model for efavirenz that addresses both the victim (CYP2B6 induction) and perpetrator (CYP2B6 and CYP3A4 induction) properties of efavirenz.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þWe present our best practice approach for PBPK model development, using efavirenz as an example, where a stepwise "matrix" approach was used to verify the different components of the model. HOW THIS MIGHT CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS þ The mechanistic model for efavirenz can be applied in clinical pharmacology studies to prospectively assess its DDI potential. As the use of PBPK to simulate the impact of coadministration with moderate CYP3A4 inducers is commonplace, a unified and verified efavirenz PBPK model within the public domain can streamline PBPK packages in regulatory submissions.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor. Daily therapy, including efavirenz (600 mg) with tenofovir (300 mg) and emtricitabine (200 mg) or lamivudine (300 mg), is recommended as an alternative treatment for human immunodeficiency virus-infected individuals aged 3 years, or first-line treatment in some populations, including pregnant women. 1 From a clinical pharmacology perspective, efavirenz is a well-known perpetrator of drug-drug interactions (DDIs) and one of the DDI properties of significant concern is moderate CYP3A4 induction. Efavirenz reduces the systemic exposures of coadministered, antiviral drugs, such as boceprevir, simeprevir, dolutegravir, amprenavir, and indinavir. [2] [3] [4] [5] [6] As such, regulatory agencies expect the pharmaceutical industry to quantify the DDI potential of CYP3A4-substrate investigational drugs because of efavirenz coadministration, especially if the investigational drugs are expected to be coprescribed in the target patient populations. One of the recently accepted approaches to quantify the DDIs perpetrated by efavirenz is the application of physiologically based pharmacokinetic (PBPK) modeling and simulation. In fact, several PBPK models for efavirenz were recently used to support the clinical pharmacology reviews of new drug applications with focus on assessing the modest CYP3A4 induction effect. [7] [8] [9] There have been several studies in the literature that reported the application of PBPK models to predict the interindividual variability in efavirenz pharmacokinetics (PKs) due to CYP2B6 pharmacogenetics, and to support dose adjustment. [10] [11] [12] A comparison of all available efavirenz models in the literature revealed that there are differences in several of the key model input parameters (e.g., plasma protein binding, CYP3A4/2B6 induction parameters). These differences perhaps reflect the fact that many of these efavirenz models are "fit-for-purpose" and the aims of the simulations were different. Therefore, a unified mechanistic model that addresses both the victim and perpetrator properties of efavirenz is still lacking. Development of a mechanistic model for efavirenz requires accounting for all the key elements of absorption, distribution, metabolism, excretion and DDI properties, validating/verifying these key elements with independent datasets, and addressing any remaining uncertainty of key input parameters.
Efavirenz is a known victim of DDIs and a few drugs have been reported to induce (e.g., rifampin) or inhibit (e.g., voriconazole) efavirenz elimination. 13, 14 Efavirenz is predominantly cleared by hepatic metabolism and in vitro studies using human liver microsomes showed that CYP2B6 and CYP2A6 were the predominant CYPs involved in the formation of 8-and 7-hydroxyefavirenz, respectively. 15 Clinical studies in patients with human immunodeficiency virus have repeatedly shown that CYP2B6 genetic variants with impaired function are associated with higher efavirenz exposure. 16, 17 Efavirenz induces its own clearance via the autoinduction of CYP2B6 upon multiple dosing. 18, 19 Thus, in order to construct a robust victim drug model, it is essential to obtain a robust estimate for the contribution (fm) of CYP2B6 and CYP3A4 to efavirenz clearance at baseline. In the absence of a clinical study with a strong CYP2B6 inhibitor, the fm CYP2B6 from in vitro metabolism data was verified by comparing the predicted autoinduction effect with observed data.
Efavirenz exhibits several DDI properties as a perpetrator. Efavirenz induces CYP2B6 activity in vivo, as demonstrated by a 2.3-fold increase in the area under the plasma concentration-time curve (AUC) ratio of hydroxybupropion: bupropion after 600 mg efavirenz administration for 2 weeks. 20 Efavirenz is a moderate inducer of CYP3A4 activity in vivo, as demonstrated by 1.9-and 4.5-fold increases in systemic and oral alfentanil clearances after efavirenz administration for 2 weeks (600 mg q.d.). 18 In the literature, efavirenz induction of CYP3A4 activity has been quantitatively characterized in human hepatocytes and applied for in vitro-in vivo extrapolation (IVIVE) of CYP3A4 induction effect. 21 Such data are sparse for CYP2B6 activity and successful IVIVE for CYP2B6 induction using a CYP2B6 marker substrate has not been shown. 22 In the current study, we utilized CYP3A4 and CYP2B6 induction data measured in the same donors of human hepatocytes, to minimize interlaboratory and interdonor variability in the measured induction effect. In addition, organ-specific induction of hepatic but not intestinal CYP3A4 has been observed with efavirenz treatment, at least at the expression level, 23, 24 an apparent phenomenon that has remained unexplained.
Although the use of a workflow approach to develop PBPK models has been recommended, 25 a recent analysis of published PBPK models highlighted that important information is often missing. 26 The specific aim of this study was to demonstrate the use of a stepwise "matrix" approach in the development of a verified and unified PBPK model for efavirenz to: (1) predict the modest induction effect on CYP3A4 victim drugs; (2) predict the induction effect on CYP2B6 victim drugs; (3) predict single-dose and multiple-dose efavirenz PK considering the autoinduction effect.
METHODS

Simulations using PBPK modeling
The Simcyp (version 14.1) population-based PBPK simulator (Simcyp Ltd, Sheffield, UK) was used to simulate the PK of efavirenz and relevant DDIs with efavirenz in virtual healthy volunteers. The coefficient of variance (CV) for liver CYP2B6 abundance was modified from the Simcyp (version 14.1) default value of 122 to 60%, to better recover the PK variability for CYP2B6 substrates observed clinically (e.g., CV of 55% for efavirenz oral clearance at 600 mg q.d. dosing in 107 human immunodeficiency virus-infected patients genotyped as CYP2B6 extensive metabolizers). 17 The metric for assessing predictive performance of PK parameters or DDIs was the predicted/observed ratio [5 predicted mean exposure (ratio)/observed mean exposure (ratio)] fall within a predefined criterion of a 1.5-fold range. The exposure was defined as maximum plasma concentration (C max ) or AUC. Several success criteria (1.25-fold or 2-fold range) have been used in the literature. [27] [28] [29] Here, a 1.5-fold range was chosen on the basis of the intrinsic PK variability of efavirenz, 30 as well as the moderate-to-mild extent of efavirenz perpetrated DDIs. 29 Development of efavirenz base model Development of the base model is summarized below and described in full in Supplementary Information.
The 600 mg q.d. dosing regimen was the primary focus for model development because this is the recommended clinical dosing regimen. The model performance was also evaluated for 400 mg dose when data are available, as there is an effort to reduce efavirenz dosage to lower drug costs. 17 The efavirenz model was developed based on in vitro data and refined using clinical PK data following oral administration. When data were obtained from more than one study, mean values were used.
The initial base model used in vivo oral clearance (CL po 5 9.07 L/h; 26% CV) (unpublished data provided by Bristol Myers Squibb) obtained from multiple dose administration as the clearance input. Volume of distribution at steady state (V ss ) was estimated from clinical data because of the uncertainty in efavirenz fu p and logP and the high sensitivity of the predicted V ss to these parameters. 31 In vitro CYP3A4 and CYP2B6 induction data, measured in the same donors (n 5 4) of human hepatocytes, were incorporated into the model (Supplementary Information).
Base model verification
Simulations were run using the base model and CYP3A4 induction in the liver and gut was evaluated and refined based on the predicted effect of efavirenz 600 mg q.d. on alfentanil i.v. and p.o. PK. The simulated trial designs are described in Supplementary Information.
CYP3A4 induction in the refined model was then independently verified based on the prediction of the effect of efavirenz 600 mg q.d. on maraviroc, atazanavir, and clarithromycin PK. A published maraviroc model 32 was used with one modification: predicted V ss (5 1.7 L/kg) replaced observed V ss and was used in the final model to better recover the observed maraviroc C max following 100 mg 
Development of efavirenz final model
The final input parameters for the model are summarized in Table 1 . 12, 15, 19, 21, [33] [34] [35] [36] [37] [38] [39] Final model development is summarized below and full details are provided in Supplementary Information.
The absorption following a daily oral dose of efavirenz was described as a first-order process after a lag time (t lag 5 0.36 h) with fraction absorbed of 0.67 33 and absorption rate constant of 0.41 h 21 . The absorption rate constant and t lag were estimated from fitting the clinical kinetic data obtained following a single oral dose of 100 mg efavirenz (unpublished data provided by Bristol Myers Squibb). A minimal PBPK model 40 with a single-adjustment compartment (SAC) was used as the distribution model. The addition of an single-adjustment compartment was necessary to recover the shape of the plasma concentration-time profiles beyond 24 hours postdosing. The estimated V sac is 1.1 L/kg associated with k in and k out of 0.29 and 0.09 hour 21 , respectively. In vitro data describing the enzyme kinetics for efavirenz in human liver microsomes, 15, 41 underpredicted clearance and so were not used in the final model. Instead, input parameters for CL int were back-calculated from observed mean CL po (5 5 .87 L/hr; single dose) 15, 19 using fm data ; f u,inc of 0.15 was applied based on sensitivity analysis in the range of 0.1-0.5 (per experiment values) CYP3A4 Ind max (fold) 9.9 Determined in human hepatocytes based on mRNA levels and calibrated against rifampin data 34 MW, molecular weight; logP, log octanol/buffer partition coefficient (neutral species); B:P, blood-to-plasma ratio; f a , fraction absorbed; k a , absorption rate constant; BMS, Bristol Myers Squibb; V ss , volume of distribution at steady state; PBPK, physiologically based V sac , volume of the single-adjusting compartment; k in and k out , first order rate constants which act on the masses of drug within the systemic compartment and the SAC respectively; CL R , renal clearance; CL/ F, oral clearance; CL int , intrinsic clearance; IndC 50 , inducer concentration that support half maximal induction; HLM, human liver microsome; F u,inc , the fraction unbound in an in vitro hepatocyte incubation.
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derived from in vitro data. 15 The contribution of CYP2B6, 2A6, 1A2, and 3A4 to efavirenz metabolism was assigned to 62%, 26.6%, 4.6%, and 4.6%, respectively. Although there are no suitable clinical DDI studies with a strong inhibitor of CYP2B6 to independently verify the fm CYP2B6 , the minor contribution of CYP3A4 is consistent with an itraconazole DDI study demonstrating negligible effect on efavirenz PK, albeit in Korean subjects. 42 Final model verification The final model was verified based on the prediction of the kinetics of efavirenz following single or multiple oral doses. Plasma concentration-time profiles and PK parameters (400 mg and 600 mg q.d. data) provided by Bristol Myers Squibb were used.
RESULTS
Workflow for model development and verification strategy
The model development and verification strategy are outlined in Figures 1 and 2 . The initial step involved assessment and optimization of CYP3A4-mediated induction by efavirenz as the perpetrator using clinical kinetic data to drive the model. Alfentanil (both i.v. and oral formulations) was used as the CYP3A4 victim drug. The resultant model was then applied to predict DDIs involving other CYP3A4 drugs, including maraviroc, atazanavir, and clarithromycin to verify the CYP4A4 induction component. A bupropion DDI study was evaluated to verify the in vitro CYP2B6 induction component of the file. Finally, the efavirenz base model was subsequently expanded by incorporating fm CYP2B6 (62%) derived from in vitro metabolism data and CYP2B6 induction data. The predictive performance for single-dose and multiple-dose efavirenz pharmacokinetics, considering the autoinduction effect, was then verified. Each step of the model development/verification is explained in detail below.
Evaluation and refinement of CYP3A4 induction in the liver and gut: prediction of the effect of efavirenz 600 mg q.d. on alfentanil i.v. and p.o. kinetics
The developed efavirenz base model was able to recover the steady-state systemic exposure of efavirenz after a 600 mg once daily dosing to healthy volunteers ( Figure 1a) . To evaluate efavirenz induction effect on hepatic and intestinal CYP3A activity, the effect of efavirenz (600 mg q. 14,15 Because efavirenz is highly bound to plasma proteins and is fairly lipophilic, we hypothesized that this phenomenon may be related to the unbound drug concentration that is available for interaction at the respective enzyme site. We tested this hypothesis by optimizing the relevant fraction unbound values in the incubation (f u,inc ) and gut (f u,gut ) and comparing the predicted alfentanil i.v. and p.o. AUC ratio due to efavirenz treatment with reported data. A sensitivity analysis of f u,inc in the range of 0.1-0.5 was conducted to evaluate its effect on the predicted alfentanil i.v. AUC ratio (Figure 3a) . The results Application of the efavirenz base model (f u,gut 5 1) resulted in a significant overprediction of the alfentanil p.o. AUC ratio: the predicted AUC ratio was 0.08 vs. an observed AUC ratio of 0.22. This result suggests that when not accounting for binding in the intestine, the induction of intestinal CYP3A4 was overpredicted. Sensitivity analysis (Figure 3b) showed that when f u,gut was set to the lowest reported f up (5 0.005), the predicted alfentanil (p.o.) AUC ratio was 0.28 (90% CI 5 0.26-0.30), which was comparable to the observed AUC ratio of 0.22 (90% CI5 0.16-0.30; Figure 1c) . The corresponding changes in active CYP3A4 are 3.3-fold and 1.5-fold induction in the liver and gut, respectively (Figure 4a,b) . The differential CYP3A4 induction profiles in the liver and gut are conceptually consistent with the findings that efavirenz (400 mg q.d.) caused organ-specific induction of hepatic but not intestinal CYP3A4 at the expression level. 23, 24 Independent verification of CYP3A4 induction: prediction of the effect of efavirenz 600 mg q.d. on maraviroc, atazanavir, and clarithromycin PKs The alfentanil, maraviroc, atazanavir, and clarithromycin models were independently verified with ketoconazole DDI studies (Supplementary Information).
The effect of efavirenz treatment (600 mg q.d. for 14 days) on maraviroc systemic exposures (100 mg b.i.d. for 14 days) were simulated (Figure 1d) . The predicted maraviroc AUC ratio and C max ratio were 0.38 (90% CI 5 0.36-0.40) and 0.44 (90% CI 5 0.42-0.46), respectively, compared to the observed AUC ratio of 0.49 (90% CI 5 0.41-0.57) and C max ratio of 0.44 (90% CI 5 0.30-0.62). 43 The model predictions were within 1.3-fold of the observed values ( Table 2) .
The effect of efavirenz treatment (600 mg q.d. on days 7-20) on atazanavir systemic exposures (400 mg q.d. for 20 days) was simulated. The predicted atazanavir AUC ratio and C max ratio were 0.43 (90% CI 5 0.40-0.47) and 0.57 (90% CI 5 0.54-0.61), respectively, compared to the observed AUC ratio of 0.26 (90% CI 5 0.22-0.32) and C max ratio of 0.41 (90% CI 5 0.33-0.51). 44 The model predictions were within 1.7-fold of the observed values ( Table 2) .
The effect of efavirenz treatment (400 mg q.d. for 7 days) on clarithromycin systemic exposures (500 mg every 12 hours for 7 days) was simulated. The predicted clarithromycin AUC ratio and C max ratio were 0.36 (90% CI 5 0.32-0.39) and 0.54 (90% CI 5 0.51-0.57), respectively, compared to the observed AUC ratio of 0.61 (90% CI 5 0.54-0.70) and C max ratio of 0.74 (90% CI 5 0.65-0.85). 44 The model predictions were within 1.7-fold of the observed values ( Table 2) Figure 2a and Table 2 ). The predicted hydroxybupropion (p.o.) AUC ratio and C max ratio were 1.44 (90% CI 5 1.42-1.53) and 1.58 (90% CI 5 1.57-1.68), vs. the observed AUC ratio of 1.0 (90% CI 5 0.81-1.2) and C max ratio of 1.5 (90% CI 5 1.2-1.8; Figure 2b and Table 2 ).
When competitive inhibition of CYP2B6 (Ki: 2.96 mM) and CYP3A4 (Ki: 40.3 mM) 45 was included into the model, there was little or no impact on predicted interaction ratios (e.g., predicted bupropion AUC ratio and C max ratio 0. 45 This simulation incorporated the in vitro CYP2B6 Ki of 2.96 mM for efavirenz determined in pooled human liver microsomes. 45 Best
efavirenz means the effect of competitive inhibition in vivo cannot be verified and knowing the overall impact on the predicted DDI is negligible, competitive inhibition was not included in the final model.
Verification of final model:prediction of the kinetics of efavirenz following single or multiple oral doses
The efavirenz base model was expanded to include fm data derived from human liver microsome data (see Supplementary Information). Mean simulated and observed plasma efavirenz concentrations following daily dosing of 600 mg efavirenz for 7-14 days are overlayed in Figure 2c (day 7) and Figure 2d (day 1 and 14). Simulated and observed mean C max and AUC values of efavirenz following 400 to 600 mg single dose and multiple dose of efavirenz are shown in Table 3 . The predicted/observed mean C max ranged from 0.86-1.50, and the mean AUC ranged from 0.73-1.39. The model based on in vitro induction parameters determined in human hepatocytes, predicted 1.7-fold autoinduction of efavirenz oral clearance following efavirenz 600 mg q.d. for 7-14 days, consistent with the reported 1.6-to 1.7-fold autoinduction in efavirenz oral clearance following 600 mg q.d. for 14 days.
18,19
DISCUSSION
In the current study, we sought to develop a unified mechanistic model for efavirenz that addresses both the victim (CYP2B6 induction) and perpetrator (CYP2B6 and CYP3A4 induction) properties of efavirenz that, in turn, accounts for its changing clearance on multiple dosing due to autoinduction. Although this is not the first report of a PBPK model for efavirenz, we believe it is the first model that (1) demonstrates adequate predictive performance for CYP3A4 and CYP2B6 induction as well as autoinduction, and (2) accounts for organ-specific induction of CYP3A4 by verifying the model predictions with independent clinical datasets. Furthermore, in response to calls for standardization of PBPK model development and verification, 26, 46 we provide this as a case study demonstrating our recommended workflow for the development of complex models for the application of DDI prediction.
During model development, three drug-specific parameters were identified to be associated with significant variability or uncertainty: f u,p , f u,inc , and f u,gut . The f u,p is a key parameter that feeds into the prediction of CL po , V ss , and DDIs. To address the variability in reported f u,p , we constructed a base model for efavirenz using in vivo CL po and V ss to recover the steady-state systemic exposures of efavirenz following multiple daily doses of 600 mg. This "model reduction" approach was necessary to allow the evaluation of CYP3A4 induction in isolation from all other confounding factors. The highest reported f u,p value was required in the final model to predict any appreciable CYP3A4 induction in vivo. The f u,inc is the free fraction in the in vitro incubation that impacts on the unbound IndC 50 . The f u,gut is the free fraction of drug in the enterocyte that is available for metabolism, inhibition, and induction. The optimization of f u,inc and f u,gut values, based on both alfentanil i.v. and p.o. DDI data, respectively, ensured that the developed model captured the differential CYP3A4 induction profiles in the liver and intestine. The uncertainty around f u,inc was further resolved experimentally by obtaining two independent measurements, one using the same protocol as used in the hepatocyte induction experiments. 34 The uncertainty around f u,gut , on the other hand, cannot be resolved experimentally. This is because nonspecific binding values generated in intestinal tissue homogenates do not account for physiological factors, such as the villous blood flow maintaining a "sink" condition. Uncertainty in f u,gut , was therefore, addressed through sensitivity analysis and verification with alfentanil p.o. DDI data. Once these identified issues had been addressed, the efavirenz base model was subsequently expanded by incorporating CYP2B6 induction data, and verified with a bupropion DDI study, before finally the fm CYP2B6 derived from in vitro data were included.
A "matrix approach" was used to independently verify the perpetrator properties of efavirenz: (1) alfentanil i.v. and p.o. DDI studies were utilized to refine CYP4A4 induction component; (2) maraviroc, atazanavir, and clarithromycin It is important to note that both atazanavir and clarithromycin are potent CYP3A4 mechanism-based inhibitors. Therefore, the DDI mechanisms are more complex than those involved in the alfentanil and maraviroc DDI. For this reason, the model predictions being within twofold of the observed DDIs were deemed to be acceptable. 27, 46 The efavirenz model sucessfully predicted the bupropion DDI magnitude with coadministration of multiple oral dosing of 600 mg efavirenz. To our knowledge, successful IVIVE of CYP2B6 induction by efavirenz using a CYP2B6 marker substrate, such as bupropion, has not been shown in the literature. Interestingly, the predicted 1.4-fold increase in hydroxybupropion (p.o.) AUC vs. the observed negligible effect on hydroxybupropion AUC, indicates that the elimination of hydroxybupropion (by unknown mechanisms) may be induced by efavirenz treatment, which was not considered in the simulation. Overall, in 8 of 10 (AUC or AUC ratio) and 9 of 9 (C max or C max ratio) of the cases, the predictions were within the predefined 1.5-fold range. In 4 of 10 (AUC or AUC ratio) and 4 of 9 (C max or C max ratio) of the cases, the predictions were within a more stringent criterion of a 1.25-fold range.
The developed efavirenz model, incorporating fm CYP2B6 (62%) derived from in vitro metabolism data, and CYP2B6 and CYP3A4 induction data obtained from the same human hepatocytes donors, predicted 1.7-fold autoinduction of efavirenz oral clearance following efavirenz 600 mg q.d. for 7-14 days. This is consistent with the reported 1.6-to 1.7-fold autoinduction of efavirenz oral clearance following 14 days of 600 mg q.d. 18, 19 One limitation of the efavirenz model is that fm CYP2B6 derived from in vitro data is considered to be associated with uncertainty, due to the cross-reactivity of ticlopidine with CYP2C19. 47 Here, the successful prediction of the extent of autoinduction provided verification of fm CYP2B6 for efavirenz , albeit to a limited extent. Literature models 7, 8, 22 based on CYP2B6 and CYP3A4 induction parameters obtained from different human hepatocytes donors, predicted autoinduction effect of nearly threefold, which may indicate an overprediction of the CYP2B6 induction effect or error in fm CYP2B6 . Alternatively, the discrepancy in the estimated magnitude of autoinduction from clinical data may stem from the variability in single-dose PK parameters, and selections of clinical studies that reported both single-dose and multiple-dose PK in the same individuals.
Unlike IVIVE of CYP3A4 induction, for which an in vivo calibrator (i.e., rifampin) has been developed and qualified, 34 relatively little is known about the extrapolation of in vitro data to the in vivo and an in vivo calibrator is not available for CYP2B6. It has been well-established in the literature that for CYP3A4, there is a strong correlation between mRNA and activity data. 48 This may not be the case for CYP2B6 due to the fact that CYP2B6 induction is CAR-mediated, whereas CYP3A4 induction is PXR-mediated. Here, in vitro CYP2B6 induction parameters based on CYP2B6 activity (hydroxybupropion formation) were used to drive the in vivo CYP2B6 induction without further calibration, and appeared to be successful in predicting both the autoinduction by efavirenz and the bupropion DDI. These data suggest that for IVIVE of CYP2B6 induction, an in vivo calibrator may not be necessary, although this awaits further confirmation by predicting the effect of other strong-to-moderate CYP2B6 inducers, including rifampin, carbamazepine, and ritonavir on bupropion PK from in vitro data.
In conclusion, the developed and verified model for efavirenz can be applied in clinical pharmacology studies to prospectively assess both the victim DDI potential (CYP2B6 induction) and perpetrator DDI potential (CYP2B6 and CYP3A4 induction) of efavirenz. Furthermore, we have demonstrated a recommended workflow for the development of PBPK models for complex drugs that induce their own metabolism as well as that of other (victim) drugs. 
